Andreas Argyrides
Stock Analyst at Oppenheimer
(4.53)
# 261
Out of 4,969 analysts
107
Total ratings
54.35%
Success rate
24.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Initiates: Outperform | $77 | $35.83 | +114.90% | 1 | Sep 3, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $6.80 | +194.12% | 2 | Aug 15, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $34 → $13 | $13.10 | -0.76% | 2 | Aug 6, 2025 | |
| KALA KALA BIO | Assumes: Outperform | $15 | $14.47 | +3.66% | 1 | Jun 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $36.62 | +66.58% | 1 | Jun 2, 2025 | |
| AQST Aquestive Therapeutics | Assumes: Outperform | $15 → $7 | $4.80 | +45.83% | 5 | Jun 2, 2025 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $3 | $1.60 | +88.09% | 2 | May 29, 2025 | |
| LQDA Liquidia | Downgrades: Underperform | $13 | $28.54 | -54.45% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.45 | +788.89% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $26.15 | +244.17% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.31 | +289.61% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $15.43 | -2.79% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $200.20 | -9.59% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $13.80 | +153.72% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $3.82 | +581.52% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $57.30 | +81.50% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.34 | +1,381.48% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $2.45 | +267.35% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $10.47 | +81.47% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $16.70 | +73.65% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.19 | +128.51% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $18.30 | +1,124.04% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $26.64 | +113.96% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.78 | +799.63% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $5.29 | +89.21% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.53 | +1,786.08% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $56.51 | +23.87% | 6 | Aug 1, 2023 |
Monopar Therapeutics
Sep 3, 2025
Initiates: Outperform
Price Target: $77
Current: $35.83
Upside: +114.90%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $6.80
Upside: +194.12%
Dyne Therapeutics
Aug 6, 2025
Maintains: Outperform
Price Target: $34 → $13
Current: $13.10
Upside: -0.76%
KALA BIO
Jun 2, 2025
Assumes: Outperform
Price Target: $15
Current: $14.47
Upside: +3.66%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $36.62
Upside: +66.58%
Aquestive Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.80
Upside: +45.83%
InflaRx
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.60
Upside: +88.09%
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $28.54
Upside: -54.45%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.45
Upside: +788.89%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $26.15
Upside: +244.17%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.31
Upside: +289.61%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $15.43
Upside: -2.79%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $200.20
Upside: -9.59%
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $13.80
Upside: +153.72%
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.82
Upside: +581.52%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $57.30
Upside: +81.50%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.34
Upside: +1,381.48%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $2.45
Upside: +267.35%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $10.47
Upside: +81.47%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $16.70
Upside: +73.65%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.19
Upside: +128.51%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $18.30
Upside: +1,124.04%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $26.64
Upside: +113.96%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.78
Upside: +799.63%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $5.29
Upside: +89.21%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.53
Upside: +1,786.08%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $56.51
Upside: +23.87%